1060 / 1241
Vascular Response Markers
DCE-MRI or CT used in >100
early phase trials of anti-
vascular drugs
ΔK
trans
& IAUC
60
:
Proof-of-principle
Optimum drug dose &
schedule e.g. cediranib*,
brivanib**
O’Connor JP et al. Nat Rev Clin Oncol 2012; 9: 167-77
*Drevs J et al. J Clin Oncol 2007; 25: 3045-54; **Jonker et al.
Ann Oncol 2011; 22: 1413-9
Phase I/II trials